You are here: Industry Insights > Evotec

News List

Evotec, Boehringer Ingelheim Partner to Tackle Ophthalmologic Disorders contractpharma
January 25, 2022
Aims to identify and validate promising targets and new approaches for therapeutic interventions.
Evotec Enters Drug Discovery Collaboration with Eli Lilly and Company for Metabolic Diseases contractpharma
January 18, 2022
Collaboration will focus on kidney diseases and diabetes.
Evotec Receives German Grant for Potential Therapy Against COVID-19 contractpharma
January 04, 2022
Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.
Evotec Opens cGMP Manufacturing Facility in Redmond, WA contractpharma
August 12, 2021
Evotec SE has opened its late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD 1 US) in Redmond, Washington.
BMS, Evotec Extend Targeted Protein Degradation Alliance contractpharma
April 27, 2021
Bristol Myers Squibb has exercised its option to extend its partnership with Evotec SE in the field of targeted protein degradation, triggering an undisclosed payment to Evotec.
Evotec to Build Second Biologics Mfg. Facility in Toulouse contractpharma
April 21, 2021
Evotec SE has initiated construction of its J.POD(R) 2 EU biologics manufacturing facility at its Campus Curie in Toulouse, France. Evotec's second innovative cGMP biomanufacturing facility will employ Just - Evotec Biologics' technology that ...
Evotec Enters Master Service Agreement with Kazia Therapeutics contractpharma
April 20, 2021
Evotec SE has entered into a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company.
Evotec, Takeda Enter Multi-RNA Target Alliance contractpharma
March 23, 2021
Evotec SE has entered into a multi-RNA target alliance with Takeda Pharmaceutical Co. to discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
Just, Evotec Expand mAbs Manufacturing Contract with DOD contractpharma
February 03, 2021
Evotec SE announced that the U.S. Department of Defense (DOD) awarded its Seattle, WA-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (mAbs) for use in the development of a ...
Evotec, BMS Advance Targeted Protein Degradation Projects contractpharma
December 18, 2020
The first two targets transition into drug discovery after completing a comprehensive target validation process.

Previous page 1 2 3 4 Next page